One Brexit-proof stock that I’d buy today

Read this to find out why I think this AIM stock could deliver impressive returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Public domain.

There are not many sectors which I would consider to have an almost guaranteed long-term upside, but the one that stands out is healthcare. The world has an ageing population, therefore the potential growth of this sector could be unlimited.

One company that services this market is Craneware (LSE:CRW), a Scottish firm that sells billing software to the US healthcare industry to deliver savings for its clients. Its focus is on the largest and most competitive market in the world, which is a shrewd move as success in America gives it the best chance to carve an impressive international market share for its product. Its software is currently used by around a quarter of US hospitals so it has plenty of room to grow, and as my Foolish colleague Roland Head points out, once the products are used by hospitals it is very difficult to replace them. This helps growth as existing revenues are well protected.

Is the company overpriced?

It fits the profile that I look for in a stock, with very good return on capital employed (ROCE) of 36% and a good operating margin at 28%. These attributes make it a high quality stock and such companies normally trade at a premium. Craneware is no exception as the price-to-earnings ratio (P/E), stands at a hefty 42x. This still seems a bit rich considering a growth rate of around 15%, but is there another reason for the premium? Software companies can scale very quickly and I think a lot of market participants feel there could be a bumper set of half-year results on the way on March 5.

The trigger for the big re-rating in the share was the earlier full-year results (although it has now been dragged back by market conditions). These were good, but I think the main cause for excitement among investors was the news of a 100% increase in new sales, considering the company has an excellent retention rate, this could make for a very good year. The firm is also releasing a new product, Trisus, which it says has had positive results from early adopters. 

Backed by management

I like founder-run companies, especially where they have a lot of skin in the game, and on September 10, following the FY results, the CEO purchased £150k of stock to take his holding to 12.7%. This is a big show of confidence considering that the P/E ratio at the time was around 50, a level at which you may expect an insider to consider taking some profits.


While I personally feel that Brexit problems should be resolved long term, one of the benefits of this business is that most of its revenues come from the US, therefore the company will benefit from any falls in the pound against the dollar. Nevertheless the share price has fallen recently showing how temperamental the stock market can be in uncertain times.

With this in mind I might wait for a bit more certainty in the markets before I think about buying Craneware, but this is an exciting stock that I’d be happy to own. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Robert Faulkner owns no position in any of the shares mentioned. The Motley Fool UK has recommended Craneware. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

GSK shares plummet 15% in a week! What’s going on here?

GSK shares had a bad time last week. They're down 15% as investors' sentiment soured ahead of litigation proceedings in…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Stock market recovery: have all the bubbles now burst?

Asset bubbles keep on coming, and here's what I'm doing to navigate through them and invest for the stock market…

Read more »

Shot of an young Indian businesswoman sitting alone in the office at night and using a digital tablet
Investing Articles

How I’d invest £290 a month in UK shares for a passive income that beats the State Pension

UK shares can offer a lucrative path for passive income. Our writer considers a plan to double his State Pension.

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

3 of the best shares to buy now with £2,000

I reckon the best shares to buy now have strong growth in earnings and recent good news flow, such as…

Read more »

Young female analyst working at her desk in the office
Investing Articles

How I’m aiming for £500 a month in income from dividend stocks 

Here's my three-step plan for achieving a growing income from dividend stocks and three companies I'd use to help execute…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

UK shares are cheap! So why is Warren Buffett ignoring them and should you too?

Many British shares are trading cheaply and pay dividends. This is normally the hunting ground for Warren Buffett, yet he's…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How I’ve increased my passive income by 600%

Finding the right opportunities can bring spectacular results. Here’s how our author has managed to increase his monthly passive income…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Could lithium shares make my Stocks and Shares ISA a goldmine?

Our writer is considering buying lithium shares for his Stocks and Shares ISA. Here, he outlines the decision process he…

Read more »